News
Vietnam Investment Review on MSN1d
IBI363 earns second breakthrough therapy status for lung cancer in ChinaIBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the ...
Updated data on IBI363 monotherapy in patients with advanced NSCLC were reported (ClinicalTrials.gov, NCT05460767). As of the ...
3d
Ku itariki ya mbere y'uku kwezi, 'drone' zirenga 100 za Ukraine zarashe ku ndege z'intambara z'Uburusiya zari ku bibuga biri ...
IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized ...
Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
At this year's ASCO meeting, IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma ...
SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
SAN JOSE, Occidental Mindoro (PIA) — Agriculture Secretary Francisco Tiu Laurel Jr. announced the construction of a ...
Kọmisanna ọlọpaa nipinlẹ Ondo, Wilfred Olutokunbo Afolabi sọrọ lori awọn aṣeyọri ileeṣẹ ọlọpaa nipinlẹ naa, ati awọn ipenija ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback